 Connection
Barry Uretsky to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Barry Uretsky has written about Randomized Controlled Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.546 |
|
|
|
-
Agarwal SK, Vallurupalli S, Uretsky BF, Hakeem A. Effectiveness of colchicine for the prevention of recurrent pericarditis and post-pericardiotomy syndrome: an updated meta-analysis of randomized clinical data. Eur Heart J Cardiovasc Pharmacother. 2015 Apr; 1(2):117-25.
Score: 0.101
-
Hakeem A, Garg N, Bhatti S, Rajpurohit N, Ahmed Z, Uretsky BF. Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data. J Am Heart Assoc. 2013 Aug 07; 2(4):e000354.
Score: 0.091
-
Wang FW, Esterbrooks D, Kuo YF, Mooss A, Mohiuddin SM, Uretsky BF. Outcomes after carotid artery stenting and endarterectomy in the Medicare population. Stroke. 2011 Jul; 42(7):2019-25.
Score: 0.078
-
Uretsky BF. IIb or not IIb? Toward a rational application of left main stenting. J Am Coll Cardiol. 2010 Jun 08; 55(23):2553-5.
Score: 0.073
-
Barbagelata A, Perna ER, Clemmensen P, Uretsky BF, Canella JP, Califf RM, Granger CB, Adams GL, Merla R, Birnbaum Y. Time to reperfusion in acute myocardial infarction. It is time to reduce it! J Electrocardiol. 2007 Jul; 40(3):257-64.
Score: 0.060
-
Triska J, Uretsky BF, Pitt B, Birnbaum Y. Closing the Digitalis Divide: Back to the Basics of Randomized Controlled Trials. Cardiovasc Drugs Ther. 2023 08; 37(4):807-813.
Score: 0.040
-
Brilakis ES, Karmpaliotis D, Werner GS, Spratt JC, Uretsky BF, Luna M, Banerjee S. Developments in coronary chronic total occlusion percutaneous coronary interventions: 2014 state-of-the-art update. J Invasive Cardiol. 2014 Jun; 26(6):261-6.
Score: 0.024
-
Hakeem A, Marmagkiolis K, Hacioglu Y, Uretsky BF, Gundogdu B, Leesar M, Bailey SR, Cilingiroglu M. Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: Comprehensive systematic review and meta-analysis of randomized controlled trials. Cardiovasc Revasc Med. 2013 Nov-Dec; 14(6):349-55.
Score: 0.023
-
Merla R, Reddy NK, Wang FW, Uretsky BF, Barbagelata A, Birnbaum Y. Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis. Am J Cardiol. 2007 Sep 01; 100(5):770-6.
Score: 0.015
-
Sanghi P, Uretsky BF, Schwarz ER. Vasopressin antagonism: a future treatment option in heart failure. Eur Heart J. 2005 Mar; 26(6):538-43.
Score: 0.013
-
Cleland JG, Thygesen K, Uretsky BF, Armstrong P, Horowitz JD, Massie B, Packer M, Poole-Wilson PA, Ryd?n L. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J. 2001 Sep; 22(17):1601-12.
Score: 0.010
-
Shah MR, Stinnett SS, McNulty SE, Gheorghiade M, Zannad F, Uretsky B, Adams KF, Califf RM, O'connor CM. Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST. Am Heart J. 2001 Jun; 141(6):908-14.
Score: 0.010
-
Adams KF, Gheorghiade M, Uretsky BF, Young JB, Patterson JH, Tomasko L, Packer M. Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. Am Heart J. 1998 Mar; 135(3):389-97.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|